Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857076 | 0.87 | TAAR1 (0.47) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL3416256 | 0.82 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL30138659 | 0.82 | SIGMAR1 (0.53) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL1732196 | 0.82 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL1513595 | 0.82 | SIGMAR1 (0.53) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL18498768 | 0.82 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL30174362 | 0.80 | PNMT (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL30457687 | 0.80 | PNMT (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL21583913 | 0.80 | PNMT (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL7473544 | 0.80 | PNMT (0.60) | TAAR1IDO1AGXTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825249-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1749014-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-20070249834-A1 | Metal Complexes | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2007-10-25 | — | — | US | disclosed |
| EP-1749014-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005113563-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249834-A1 | Metal Complexes | SOD1, AP1M1, AP2A1 | TAAR1 1250/4885IDO1 1328/4885AGXT 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.